Dr. Shadman on Challenges With CAR T-Cell Therapy

Video

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

As with any other therapy, safety is always a priority, says Shadman; it does not matter if the therapy is effective if it is not safe. However, progress has been made in ensuring that the CAR T-cell products that are brought to market have manageable toxicities. Physicians are learning more about how to manage associated toxicities and how to decrease a patient’s risk of these toxicities, namely cytokine release syndrome and neurotoxicity.

From a practical standpoint, it is becoming a crowded space to bring new CAR T-cell products or combinations to, says Shadman. Having an FDA-approved CAR T-cell therapy is great, but it also makes it more challenging to bring a more effective product to market, he explains. It is a good problem to have, but it will slow down enrollment on clinical trials and research in terms of sequencing strategies because patients will be less likely to progress. Despite this, Shadman is confident that investigators will be able to overcome such challenges with the volume of research that is being done.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.